Bazmandegan Gholamrerza, Dehghani Mohammad Hasan, Karimifard Maryam, Kahnooji Mahmood, Balaee Parisa, Zakeri Mohammad Ali, Kamiab Zahra
Physiology-Pharmacology Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Nutr Metab Cardiovasc Dis. 2024 Apr;34(4):1014-1020. doi: 10.1016/j.numecd.2023.12.022. Epub 2023 Dec 30.
Metabolic syndrome (MetS) refers to existence of a set of risk factors for developing cardiovascular disease and diabetes. Recently, uric acid to HDL ratio has attracted attention in predicting development of diabetes and incidence of metabolic syndrome in diabetic individuals. This study was performed to investigate UHR in patients with type II diabetes as a predicting factor for metabolic syndrome.
This descriptive-analytical study examined 300 patients with type II diabetes referring to diabetes clinic of Ali-Ibn Abi-Talib hospital, Rafsanjan city in 2021, selected through convenient sampling. Data were collected by a research-made checklist (including demographic, clinical and laboratory parameters) and analyzed by SPSS 24 and chi-square, Fisher exact test, independent paired t-test, one-way analysis of variance (ANOVA), Mann-Whitney U, and receiver operating characteristic (ROC). The findings revealed that 74.33 % (95 % CI: 69 to 79.18 %) of the patients had metabolic syndrome. Further, patients with metabolic syndrome demonstrated a significantly higher mean UHR ratio and triglyceride levels compared to their counterparts without the syndrome (p = 0.002 and p < 0.001, respectively). The ROC analysis identified a UHR threshold of 8.118 % with a sensitivity of 70.32 % and specificity of 55.08 % for diagnosing metabolic syndrome development in type II diabetes (AUC: 0.621, P = 0.001, 95%CI: 0.549-0.694).
The results of the present study revealed that the prevalence of metabolic syndrome was high in diabetic patients. UHR showed good sensitivity in the diagnosis of metabolic syndrome in type II diabetes. Thus, regular monitoring of laboratory tests is recommended in patients with diabetes.
代谢综合征（MetS）指存在一组心血管疾病和糖尿病的危险因素。近来，尿酸与高密度脂蛋白比值在预测糖尿病的发生及糖尿病个体代谢综合征的发病率方面受到关注。本研究旨在调查2型糖尿病患者的尿酸与高密度脂蛋白比值（UHR），作为代谢综合征的预测因素。
本描述性分析研究于2021年对转诊至拉夫桑詹市阿里 - 伊本·阿比 - 塔利卜医院糖尿病门诊的300例2型糖尿病患者进行了检查，通过方便抽样选取。数据通过自行编制的检查表（包括人口统计学、临床和实验室参数）收集，并采用SPSS 24以及卡方检验、Fisher精确检验、独立配对t检验、单因素方差分析（ANOVA）、Mann - Whitney U检验和受试者工作特征（ROC）分析。结果显示，74.33%（95%置信区间：69%至79.18%）的患者患有代谢综合征。此外，与无该综合征的患者相比，患有代谢综合征的患者平均UHR比值和甘油三酯水平显著更高（分别为p = 0.002和p < 0.001）。ROC分析确定，诊断2型糖尿病患者代谢综合征发生的UHR阈值为8.118%，灵敏度为70.32%，特异度为55.08%（曲线下面积：0.621，P = 0.001，95%置信区间：0.549 - 0.694）。
本研究结果显示糖尿病患者中代谢综合征的患病率较高。UHR在诊断2型糖尿病患者的代谢综合征方面表现出良好的灵敏度。因此，建议对糖尿病患者定期监测实验室检查。
